Literature DB >> 17694386

Comparative efficacy of low dose, daily versus alternate day plasma exchange in severe myasthenia gravis: a randomised trial.

Isha Trikha1, Sumit Singh, Vinay Goyal, Garima Shukla, Rama Bhasin, Madhuri Behari.   

Abstract

OBJECTIVE: To evaluate the comparative efficacy of low dose daily versus alternate day plasma exchange in patients with severe myasthenia.
METHODS: Thirty three patients with myasthenia gravis (Osserman's stage II b and III) were randomized to receive alternate day (n = 17) or daily low dose plasma exchange (n = 16). Plasma exchange were carried on each patient, number of exchanges varying subject to their requirements and 20-25 ml/kg plasma was removed during each session. Myasthenia gravis disease scale (MGDS) score was evaluated before and after the procedure. Time to wean off ventilator, removal of nasogastric tube and total duration of hospital stay were also assessed.
RESULTS: There was no statistically significant difference between daily vs. alternate day group with regards to change in MGDS score, percentage change in MGDS score, and complication rates. A decreased hospital stay was observed in patients on daily plasma exchange which almost reached statistical significance.
CONCLUSION: We conclude from our study that daily and alternate day plasma exchange are similar in their efficacy and complication rates, however the daily schedule could be a preferred modality due to decreased hospital stay.

Entities:  

Mesh:

Year:  2007        PMID: 17694386     DOI: 10.1007/s00415-006-0235-7

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  26 in total

1.  Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis.

Authors:  J Rønager; M Ravnborg; I Hermansen; S Vorstrup
Journal:  Artif Organs       Date:  2001-12       Impact factor: 3.094

2.  Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group.

Authors:  P Gajdos; S Chevret; B Clair; C Tranchant; C Chastang
Journal:  Ann Neurol       Date:  1997-06       Impact factor: 10.422

3.  Plasmapheresis in myasthenia gravis.

Authors:  M E Seybold
Journal:  Ann N Y Acad Sci       Date:  1987       Impact factor: 5.691

4.  Role of plasmapheresis in preparing myasthenic patients for thymectomy: initial results.

Authors:  P A Spence; J E Morin; M Katz
Journal:  Can J Surg       Date:  1984-05       Impact factor: 2.089

5.  [Plasmapheresis for myasthenia gravis].

Authors:  J Newsom-Davis; A Vincent; S G Wilson; C D Ward; A J Pinching; C Hawkey
Journal:  N Engl J Med       Date:  1978-02-23       Impact factor: 91.245

6.  Single donor plasma in therapeutic plasma exchange for myasthenia gravis.

Authors:  R Mantegazza; E Bruzzone; B Regi; D Peluchetti; M Marconi; G Sirchia; V Borroni; F Cornelio
Journal:  Int J Artif Organs       Date:  1987-09       Impact factor: 1.595

7.  Postoperative respiratory care after transsternal thymectomy in myasthenia gravis. A 3-year experience in 53 patients.

Authors:  D R Gracey; M B Divertie; F M Howard; W S Payne
Journal:  Chest       Date:  1984-07       Impact factor: 9.410

8.  A short plasma exchange protocol is effective in severe myasthenia gravis.

Authors:  C Antozzi; M Gemma; B Regi; E Berta; P Confalonieri; D Peluchetti; R Mantegazza; F Baggi; M Marconi; F Fiacchino
Journal:  J Neurol       Date:  1991-04       Impact factor: 4.849

9.  Effect of prethymectomy plasma exchange on postoperative respiratory function in myasthenia gravis.

Authors:  G d'Empaire; D C Hoaglin; V P Perlo; H Pontoppidan
Journal:  J Thorac Cardiovasc Surg       Date:  1985-04       Impact factor: 5.209

10.  Plasmaexchange in the treatment of myasthenia gravis associated with thymoma.

Authors:  L Gogovska; R Ljapcev; M Polenakovic; L Stojkovski; M Popovska; L Grcevska
Journal:  Int J Artif Organs       Date:  2003-02       Impact factor: 1.595

View more
  3 in total

1.  [Report from NeuroUpdate in Wiesbaden (13/14 February 2009)].

Authors:  M Dieterich; G F Hamann
Journal:  Nervenarzt       Date:  2009-06       Impact factor: 1.214

2.  Current and emerging treatments for the management of myasthenia gravis.

Authors:  Sivakumar Sathasivam
Journal:  Ther Clin Risk Manag       Date:  2011-07-22       Impact factor: 2.423

Review 3.  Therapeutic Plasma Exchange: For Cancer Patients.

Authors:  Yuru Hu; Hanshan Yang; Shaozhi Fu; Jingbo Wu
Journal:  Cancer Manag Res       Date:  2022-02-02       Impact factor: 3.989

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.